Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Protein Effect||loss of function|
|Gene Variant Descriptions||STK11 loss indicates loss of the STK11 gene, mRNA, and protein.|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|STK11 loss||lung cancer||resistant||unspecified PD-1 antibody||Preclinical||Actionable||In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127).||26833127|
|STK11 loss||lung non-small cell carcinoma||no benefit||Vistusertib||Clinical Study - Cohort||Actionable||In a Phase II trial (NLMT), Vistusertib (AZD2014) treatment resulted in an observed objective response rate (ORR) of 0% (0/17), durable clinical benefit rate (DCBR) of 12% (2/17), and medial progression-free survival (PFS) of 2.3 months in patients with non-small cell lung cancer harboring STK11 loss, with Bayesian posterior probability for OR and DCBR of <0.01 and 0.06, respectively, thus the cohort was closed due to futility (PMID: 32669708, NCT02664935).||32669708|
|STK11 loss||Advanced Solid Tumor||no benefit||Metformin||Preclinical - Cell culture||Actionable||In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, PMID: 18006825).||18006825 17062558|
|ERBB2 act mut STK11 loss||breast cancer||sensitive||AZD8055||Preclinical||Actionable||In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).||25436981|
|STK11 D194E STK11 loss||pancreatic cancer||predicted - sensitive||Everolimus||Case Reports/Case Series||Actionable||In a clinical case study, a pancreatic cancer patient with Peutz-Jeghers syndrome harboring STK11 D194E and loss of heterozygosity of the other STK11 allele in the tumor achieved a partial response following treatment with Afinitor (everolimus), but progressed after 9 months (PMID: 21189378).||21189378|